ASCO 2020: Genentech’s Novel anti-TIGIT Therapy Shows Promise in Phase II Lung Cancer Trials
By T. Chakraborty, Ph.D. Tiragolumab’s encouraging data bolster the fight against lung cancer, the second most common cancer with a 5-year survival rate of 24%. Lung cancer is one of …
Read More